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Background: Although left ventricular (LV) global systolic longitudinal strain (GLS) reliably and accurately as-
sesses LV systolic function and is also a powerful prognostic predictor, the importance and prognostic value of
GLS in end-stage renal disease patients receiving maintenance peritoneal dialysis (PD) remain unclear. This
study sought to determine the prognostic value of GLS in chronic PD patients.
Methods: This prospective study collected clinical and echocardiographic data from 106 stable PD patients
(50.0 ± 13.9 years, 45% male) in a dialysis unit of a university hospital. These patients were enrolled from
April 2010 to June 2010 and followed until August 2013 (follow-up duration 30.3 ± 14.3 months). The primary
outcomes were the presence of major adverse events (MAEs), deﬁned as all-cause mortality, and major adverse
cardiovascular cerebral events (MACCEs), i.e. cardiovascular death, cardiac hospitalization, and stroke.
Results: Twenty-nine patients (27%) reported a primary outcome. Patients withMAEs hadworse LV systolic func-
tion (MAEs vs. no MAEs,−14.8 ± 2.8 vs.−17.1 ± 2.5%, p=0.003). Using multivariate Cox regression analyses,
being male, having a history of heart failure, diabetes mellitus, an increased pulse pressure (≥60 mm Hg), and
GLS≥−15%were independent predictors of MAEs. The independent risk factors of MACCEswere a history of di-
abetesmellitus, an increased pulse pressure, andGLS≥−15%. After comparison of the overall log likelihood χ2 of
the predictive power, GLS was found to add prognostic information to a model based on traditional risk factors.
Conclusion: GLS ≥−15% provided additional prognostic information that allowed for the early identiﬁcation of
high-risk PD patients.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Despite signiﬁcant advances in dialysis, mortality and morbidity in
end-stage renal disease (ESRD) patients receiving maintenance hemo-
dialysis or peritoneal dialysis (PD) remain high and are important
unresolved issues [1,2]. The identiﬁcation of high-risk patients would
allow physicians to optimize therapeutic interventions, which may
lower morbidity and mortality. Cardiovascular diseases, such as leftology, Department of Internal
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nd Ltd. This is an open access article uventricular (LV) hypertrophy, coronary artery disease (CAD), and
heart failure (HF), frequently occur in dialysis patients [3–5]. Important-
ly, cardiac structural and functional abnormalities are associated with
high mortality in ESRD patients [6–8]. Although cardiac geometry and
function in ESRD patients have been extensively studied using conven-
tional echocardiography, this method provides a semi-quantitative
evaluation and cannot detect subclinical cardiac dysfunction [9].
Compared with conventional echocardiographic measurements,
speckle-tracking echocardiography (STE) with myocardial deformation
analysis (2D strain) is amore accurate, objective, reproducible, and sen-
sitive modality for assessing cardiac function, even among HF patients
with preserved LV ejection fraction (LVEF) and chronic kidney disease
patients [10–14]. Previous studies indicated that LV global peak systolic
longitudinal strain (GLS) is a load-independentmeasurement of LV sys-
tolic function [14–17]. In the general population, GLS is a powerful prog-
nostic predictor [18,19]. Nevertheless, the prognostic role of GLS has not
been validated in PD patients. Thus, we conducted a prospective obser-
vational study to assess the prognostic role of GLS in chronic PD
patients.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ESRDpatients on continuous PD therapy over 3monthswere eligible
for this study. These patients were prospectively screened in a single PD
unit of the National Cheng Kung University Hospital in Tainan, Taiwan.
Patients whowere between 18 and 80 years of age, did not have an ob-
vious volume overload, and were willing to join this study were en-
rolled from April 2010 to June 2010. The exclusion criteria included
HF, diagnosed according to the European Society of Cardiology HF
criteria [20], presenting with pulmonary edema in the past 6 months,
history of acute coronary syndrome in the past 6 months, chronic atrial
ﬁbrillation, moderate to severe valvular heart disease (includingmitral/
aortic regurgitation or stenosis), and inadequate echocardiographic im-
aging quality. The study adhered to the Declaration of Helsinki and was
approved by the Human Research and Ethics Committee of National
Cheng Kung University Hospital (IRB number: ER-98-219). All enrolled
patients provided informed consent.
Clinical information on co-morbidities, medical history, and cur-
rent cardiovascular medications was obtained by careful review of
each patient's medical record and a self-reported questionnaire. Pa-
tient compliance with prescribed medication regimens was reliably
ascertained. All participants were primarily dialyzed using conven-
tional lactate-buffered glucose-based PD solutions. Residual renal
function (RRF) and daily urine volume were measured from a 24-
hour urine sample. RRF was calculated as the mean of the 24-hour
creatinine clearance and urea clearance normalized to the standard
body surface area of 1.73 m2 [21]. Patients with a urine volume less
than 100 ml/day were assumed to have no RRF. PD adequacy was
evaluated by the total weekly Kt/V (product of dialyzer urea clear-
ance and treatment time divided by the urea compartment volume),
equal to 7 ∗ (24-hour urea clearance / total body water), with total
body water estimated using the Watson formula [22].
After the patient was recumbent for 15 min during the echocardio-
graphic examination, brachial arterial blood pressure was measured
by a trained nurse using a validated sphygmomanometer as previously
described [23]. Pulse pressure was calculated as the difference between
the systolic and diastolic blood pressures. A pulse pressure≥ 60mmHg
is associated with an increased risk of mortality in PD patients; there-
fore, the cut-off point for an increased pulse pressure was deﬁned as
60 mm Hg [24].
2.1. Biochemical analysis
Blood samples were collected upon study enrollment. Serum levels
of creatinine, hemoglobin, cholesterol, triglycerides, low-density lipo-
protein cholesterol, calcium, phosphate, and albumin were measured
using routine methods.
2.2. Echocardiography measurements and analysis
All the patients were examined in the left lateral decubitus position
using an ultrasound system with a 3.5-MHz probe (Vivid-i, GE
Healthcare, Horten, Norway) by one experienced cardiologist and one
well-trained echocardiographer who were blinded to all clinical details
of the patients. According to the recommendations of the American Soci-
ety of Echocardiography [25], quantiﬁcation of the LVmass index (LVMi),
LVEF, and left atrial volume index (LAVi)was performed. LV hypertrophy
was deﬁned as LVMi N 115 g/m2 formen and N95 g/m2 forwomen. Pulse
tissue Doppler imaging of the mitral annulus movement was performed
in the apical 4-chamber view when a sample volume was ﬁrst placed at
the septal side and then at the lateral side of themitral annulus. To obtain
the peak systolic (s′) and early diastolic (e′) velocities, we measured 3
end-expiratory beats and averaged these values for further analysis.
We used the average e′ velocity acquired from the septal and lateral
sides of themitral annulus to calculate the ratio of themitral inﬂow E ve-
locity to the e′ velocity (average E/e′=E / [(e′septal + e′lateral) / 2]). Two-dimensional gray-scale images in three standard apical views (i.e., apical
4-chamber, apical 2-chamber, and apical long-axis) for three cardiac cy-
cles were acquired and stored digitally with a frame rate of 50–90
frames/s for subsequent off-line analysis.
Using automated function imaging (AFI) software (EchoPAC work
station, BT11, GE Healthcare, Israel), off-line image analysis was per-
formed by two cardiologists whowere blinded to the patient clinical in-
formation. Strain and strain rate were measured using the following
protocol [11,14,17]. The peak systolic longitudinal strain was obtained
from the 3 standard apical views by AFI software, and the average
value of peak systolic longitudinal strain from 3 apical views was
regarded as GLS (Supplemental ﬁgure). Longitudinal systolic strain
rate was automatically obtained from the three standard apical views,
and six LV segments in the para-sternal short-axis view at the mid-
papillary level were then examined to obtain the circumferential strain
and systolic strain rate.
2.3. Follow-up and outcome measurements
The patients regularly visited our PD clinic from the day of enroll-
ment until death, cessation of PD, or end of the study. There was only
one patient with whom we could not follow up because of immigra-
tion to another country. The medical records of enrolled patients
during the follow-up period (April 2010 to August 2013) were care-
fully reviewed. The primary outcomes were major adverse events
(MAEs), including all-cause mortality, cardiovascular death, cardiac
hospitalization due to cardiovascular events (e.g., decompensated
HF with pulmonary congestion, CAD, fatal or non-fatal myocardial
infarction (MI), or electrocardiographically documented arrhythmia
requiring hospitalization; Supplemental Table 1), scheduled coro-
nary revascularization (i.e., percutaneous transluminal coronary an-
gioplasty and/or coronary artery bypass surgery), thromboembolic
or hemorrhagic stroke, or newly diagnosed peripheral artery disease.
The secondary outcomesweremajor adverse cardiovascular cerebral
events (MACCEs) [26], i.e., MAEs other than non-cardiovascular
death.
2.4. Statistical analysis
Continuous data are presented as the mean ± standard deviation or
as the median (interquartile range), depending on the distribution. Di-
chotomousdata are presented as numbers andpercentages. Comparisons
were conducted using Student's t-test or the Mann–Whitney U test for
continuous variables, which showed a normal or non-parametric distri-
bution, respectively. A chi-square test or Fisher's exact test was used for
categorical variables where appropriate. The relationships between con-
tinuous variables were evaluated using Pearson correlation analysis.
We did the receiver operating characteristic (ROC) curve analysis
and calculated the areas under the ROC curves (AUC) to evaluate the
prognostic performance of different LV echocardiographic parameters
for MAEs and MACCEs.
Patientswere stratiﬁed into two groups according to their GLS value.
The Kaplan–Meier method was used with a log-rank test to compare
event-free rates between strata. In this analysis, patients who received
renal transplantation or were permanently transferred to hemodialysis
were censored at the time of alternative renal replacement therapy
(RRT). A patient was not censored when he or she reached one of the
endpoints within 3 months of transferring to another RRT because
such an event should be considered as a reﬂection of health status dur-
ing the PD period.
A univariate Cox regression analysis was performed to evaluate fac-
tors associated with MAEs or MACCEs. Factors with p b 0.1 based on a
univariate analysis were used in the multivariate Cox regression analy-
sis to investigate risk factors for MAEs and MACCEs. The ﬁnal multivar-
iate Cox regression models were validated by a bootstrap resampling
procedure with 3000 samples [27,28].
Table 1
Baseline demographic and clinical characteristics, biochemical parameters, dialysis indices and echocardiographic measurements.
Total (n = 106) No MAEs (n = 77) MAEs (n = 29) pa
Age (years) 50.0 ± 13.9 48.3 ± 12.5 54.5 ± 16.2 0.07
Male, n (%) 48 (45%) 28 (36%) 20 (69%) 0.003
Body mass index (kg/m2) 22.9 ± 3.7 23.1 ± 3.9 22.5 ± 3.4 0.48
Total Kt/V 2.18 ± 0.31 2.19 ± 0.32 2.17 ± 0.27 0.76
PD duration (years)b 4.1 (1.3, 7.3) 4.2 (1.3, 8.5) 3.1 (1.4, 5.0) 0.15
SBP (mm Hg) 133.2 ± 18.4 128.9 ± 16.8 141.8 ± 19.8 0.006
DBP (mm Hg) 77.8 ± 13.1 78.4 ± 12.0 76.1 ± 15.9 0.49
Pulse pressure (mm Hg) 55.4 ± 14.3 51.5 ± 11.8 65.7 ± 15.4 b0.001
Increased pulse pressure (≥60 mm Hg), n (%) 36 (34%) 18 (23%) 18 (62%) b0.001
Heart rate (beats/min) 77.7 ± 13.1 77.5 ± 13.4 78.6 ± 10.8 0.67
Presence of RRF, n (%) 52 (49%) 34 (44%) 18 (62%) 0.10
Daily urine amount (ml)b 0 (0, 600) 0 (0, 575) 180 (0, 625) 0.28
Clinical background comorbidities, number (%)
Heart failure 6 (6%) 0 (0%) 6 (6%) b0.001
Coronary artery disease 4 (4%) 0 (0%) 4 (4%) b0.001
Diabetes mellitus 23 (22%) 10 (13%) 13 (45%) b0.001
Hypertension 95 (90%) 68 (88%) 27 (93%) 0.72
Hypercholesterolemia 61 (58%) 45 (58%) 16 (55%) 0.76
Peripheral arterial disease 17 (16%) 13 (17%) 4 (14%) N0.99
Left ventricular hypertrophyc 64 (60%) 41 (53%) 23 (79%) 0.02
Cardiovascular drugs, number (%)
ACEIs/ARBs 35 (33%) 21 (27%) 14 (48%) 0.06
β-Blocker 46 (46%) 33 (43%) 13 (45%) 0.86
CCB 49 (46%) 35 (45%) 14 (48%) 0.80
Statin 40 (38%) 29 (38%) 11 (38%) 0.98
Serum biochemical parameters
Calcium (mg/dl) 9.4 ± 0.9 9.5 ± 1.0 9.4 ± 0.7 0.56
Phosphate (mg/dl) 5.1 ± 1.1 5.0 ± 1.1 5.2 ± 1.2 0.43
Albumin (g/dl) 4.0 ± 0.4 4.0 ± 0.4 3.9 ± 0.4 0.54
Cholesterol (mg/dl) 183.1 ± 37.1 183.4 ± 35.3 182.2 ± 42.3 0.89
Triglyceride (mg/dl)b 131.5 (91.0, 201.0) 137.0 (91.5, 192.0) 118.0 (87.0, 211.0) 0.73
LDL-C (mg/dl) 104.7 ± 34.6 106.0 ± 33.9 101.1 ± 36.6 0.53
Hemoglobin (g/dl) 10.8 ± 1.7 10.9 ± 1.8 10.5 ± 1.4 0.22
CCr (ml/min/1.73 m2)b 0 (0, 1.4) 0 (0, 1.3) 0.4 (0, 1.4) 0.30
Baseline echocardiographic measurements
LV EDVi (ml/m2)b 65.5 (53.0, 81.7) 61.1 (50.9, 79.6) 73.3 (59.0, 84.1) 0.03
LVMi (gm/m2)b 113.2 (91.1, 133.4) 102.7 (86.1, 132.2) 127.7 (113.6, 162.4) b0.001
IVCe diameter (cm) 1.2 ± 0.3 1.2 ± 0.3 1.4 ± 0.3 0.002
LV EF (%) 66.8 ± 7.7 68.1 ± 6.0 63.4 ± 10.5 0.03
s′ (cm/s) 8.9 ± 2.1 9.2 ± 1.9 8.1 ± 2.5 0.03
LV GLS (%) −16.5 ± 2.8 −17.1 ± 2.5 −14.8 ± 2.8 0.003
Longitudinal SRs (s−1) −0.92 ± 0.21 −0.96 ± 0.20 −0.82 ± 0.20 b0.001
Patients with reduced GLS (≥−15%), n (%) 31 (29%) 14 (18%) 17 (59%) b0.001
CS (%) −14.5 ± 3.9 −15.1 ± 3.9 −13.0 ± 3.5 0.01
Circumferential SRs (s−1) −1.04 ± 0.39 −1.08 ± 0.42 −0.91 ± 0.26 0.02
E (m/s)c 0.65 (0.57, 0.82) 0.63 (0.57, 0.76) 0.69 (0.59, 0.98) 0.12
A (m/s) 0.89 ± 0.23 0.86 ± 0.22 0.97 ± 0.25 0.04
E/Ab 0.74 (0.65, 0.92) 0.78 (0.66, 0.92) 0.71 (0.60, 1.02) 0.68
e′ (cm/s) 7.5 ± 2.5 7.7 ± 2.3 6.9 ± 2.9 0.19
E/e′b 9.3 (7.3 11.5) 8.7 (7.0, 11.4) 10.2 (8.0, 14.4) 0.02
LAVi (ml/m2) 28.6 ± 11.3 26.9 ± 11.0 33.0 ± 11.1 0.02
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II-receptor blocker; CCB, calcium channel blocker; CCr, creatinine clearance rate; CS, circumferential strain;
DBP, diastolic blood pressure; EDVi, end-diastolic volume index; EF, ejection fraction; E/A, early to late diastolic trans-mitral velocity ratio; E/e′, early trans-mitral velocity to tissue Doppler
mitral annular early diastolic velocity ratio; e′, tissue Doppler mitral annular early diastolic velocity; GLS, global left ventricular peak systolic longitudinal strain; IVCe, end-expiratory inferior
vena cava diameter; LAVi, left atrial volume index; LDL-C, lowdensity lipoprotein of cholesterol; LV, left ventricular; LVMi, left ventricularmass index;MAE,major adverse event; PD, peritoneal
dialysis; RRF, residual renal function; SBP, systolic blood pressure; SRs, systolic strain rate; s′, left ventricular systolic myocardial velocity.
Unless speciﬁed otherwise, data are expressed as mean ± SD or number (%).
a p value for comparison betweenpatientswith andwithoutMAEs by Student's t-test for normal distributed continuous data, nonparametric test for non-normal distributed continuous
data, and chi-square test or Fisher's exact test for categorical variables.
b Median (interquartile range).
c Left ventricular hypertrophy was diagnosed by echocardiography.
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ventional echocardiographic parameters was assessed in 4 modeling
steps: model 1 adjusted for demographic parameters, i.e. age and
gender. Model 2 adjusted for model 1 factors and LVMi and pulse
pressure. Model 3 adjusted for model 2 factors and clinical parameters
(co-morbidities).Model 4 adjusted formodel 3 factors andGLS.We per-
formed the−2log likelihood ratio statistic, following a χ2 distributionto evaluate the signiﬁcance of improvement in model prediction and p
value was based on the incremental value compared to the previous
model.
Intra- and inter-observer reliabilities of GLS measurement were
assessed in 2 sets of 30 randomly selected subjects by performing
Bland–Altman analysis [29] of agreement and calculating the interclass
correlation coefﬁcient. A two-sided p b 0.05 was considered statistically
4 Y.-W. Liu et al. / IJC Heart & Vasculature 5 (2014) 1–8signiﬁcant. All statistical analyses were performed using the IBM SPSS
software package, version 22.0 (SPSS Inc.).3. Results
Therewere 126 PD patients eligible for this study but 13 patients did
not provide informed consent. A total of 113 PD patients were prospec-
tively enrolled. However, 7 patients were excluded, including patients
who did not undergo echocardiographic examination (n = 3), had
poor echocardiographic images for analysis (n= 2), were unable to un-
dergo 2D strain analysis because of chronic atrial ﬁbrillation with a var-
iable heart rate (n= 1), and were lost to follow-up due to immigration
to another country (n=1). Therefore, 106patientswere included in the
ﬁnal analyses. The baseline demographic, clinical, and biochemical data
and echocardiographic results are summarized in Tables 1 and 2. Fifty-
four patients (51%) had no RRF. The mean total Kt/V and hemoglobin
values were 2.18 ± 0.31 and 10.8 ± 1.7 g/dl, respectively.
Themedian follow-up durationwas 30.3± 14.3months (range 1–42
months). During the follow-up period, 22 patients were permanently
transferred to maintenance hemodialysis, 7 patients underwent renal
transplantation, and 9 patients died. Seven of the deaths were not due
to cardiovascular causes (pneumonia in 2 patients, other infections in 4
patients, and malignancy in 1 patient). Twenty-two patients had one or
more cardiovascular cerebral events, including paroxysmal supraventric-
ular tachycardia (suspicion of Wolff–Parkinson–White syndrome) in 1
patient, non-fatal MI in 2 patients, angina in 5 patients, decompensated
HF with pulmonary edema in 7 patients, scheduled revascularization in
7 patients, cerebrovascular events in 4 patients, and peripheral artery
disease with/without percutaneous transluminal angioplasty in 8
patients.
Overall, 29 patients (27.3%) experienced MAEs. The enrolled pa-
tients were stratiﬁed into two groups, namely, the MAE and MAE-free
groups. Compared with the MAE-free group, the MAE group had an in-
creased pulse pressure and higher rates of CAD, HF, diabetes mellitus,
and LVH. In addition, there were more male patients in the MAE
group (Table 1).3.1. Evaluation of cardiac function (Table 1)
Sixty-four patients (60%) had LVH, and 4 patients had reduced LVEF
(LVEF b 50%). The MAE group had a slightly deteriorated LV systolic
function, represented by changes in the LVEF, s′, and GLS. Moreover,
both groups had a reverse ratio between early and late LVﬁlling velocity
(E/A), high E/e′, and high LAVi, all of which are consistent with diastolic
dysfunction.Table 2
Univariable and multivariable Cox regression analyses of major adverse events (MAEs) and ma
Variables MAEs
Univariable Multivar
HR (95% CI) p HR (95%
Age (years) 1.03 (1.002–1.06) 0.03 1.01 (0.9
Male 3.15 (1.43–6.93) 0.004 2.36 (1.0
Background history of HF 7.13 (2.85–17.8) b0.001 2.88 (1.1
Coronary artery disease 5.28 (1.81–15.4) 0.002 –
Diabetes mellitus 3.57 (1.70–7.46) 0.001 2.41 (1.1
Increased pulse pressure (≥60 mm Hg) 3.89 (1.83–8.24) b0.001 2.56 (1.1
Presence of RRF 1.85 (0.87–3.92) 0.11 –
Albumin 0.57 (0.20–1.63) 0.29 –
LVMi 1.01 (1.01–1.02) 0.001 1.00 (0.9
Reduced GLS (≥−15%) 3.95 (1.88–8.29) b0.001 2.26 (1.0
Abbreviations: CI, conﬁdence interval; HF, heart failure; HR, hazard ratio; GLS, global left ventric
function.
–: not enrolled.3.2. Prognostic indicator stratiﬁcation
Because there were many echocardiographic parameters with signif-
icant differences between the MAE and MAE-free groups, we used Pear-
son correlation analyses to determine the correlation between GLS and
these parameters, which could serve as potential prognostic factors. We
found a signiﬁcant correlation between GLS and themajority of echocar-
diographicmeasurements, including LVEDVi, LVMi, LVEF, s′, E/e′, systolic
circumferential strain, and systolic circumferential/longitudinal strain
rate (Supplemental Table 2). Compared to the LV conventional and TDI
echocardiographic parameters, GLS had the highest AUC values of
MAEs and MACCEs (Figs. 1 and 2). We subsequently did multivariate
Cox regression analyses to identify the independent echocardiographic
parameters ofMAEs andMACCEs and found that GLSwasmore powerful
than the LV conventional and TDI measurements (Supplemental
Table 3). Therefore, we did not include these parameters in the following
Cox regression analyses.
In a recent study, we demonstrated that GLS ≥ −15% was an in-
dependent prognostic predictor of all-cause mortality in clinically
stable hemodialysis patients with preserved LVEF [17]. In addition,
several studies have shown that GLS ≥ −15% should be considered
pathological [23–25]. Therefore, we deﬁned the cutoff point of GLS
to be−15%.
Using a univariate Cox regression analysis, we subsequently found
several potential MAE and MACCE risk factors, including old age, male
gender, history of HF, CAD, diabetes, increased LVMi, increased pulse
pressure (≥60mmHg), and GLS≥−15% (Table 2). However,many co-
variates in the multivariate Cox model may provide an unreliable esti-
mate because there were only 29 patients who reached a primary
outcome. Therefore, we also used 5 multivariate Cox regression models
to assess independent prognostic predictors ofMAEs andMACCEs (Sup-
plemental Tables 4 and 5). First, we performedmultivariate Cox regres-
sion analysis with well-known prognostic risk factors of PD patients
(model 1). We did not include CAD in model 2 because it was not a sig-
niﬁcant marker in model 1 and there were only 4 enrolled PD patients
who had a history of CAD; thus, the regression analysis result was con-
sistentwithmodel 1.We added the factor of GLS inmodel 3 and the fac-
tors of GLS≥−15% and CAD inmodel 4 (Table 2, Supplemental Tables 4
and 5). We also performed an analysis of model 5 because LAVi was re-
ported as a prognostic indicator in PD patients; however, we found that
LAVi was not signiﬁcant in our PD patients. From thesemultivariate Cox
regression models, we determined that male gender, history of HF and
diabetes, increased pulse pressure, and GLS≥−15% are signiﬁcantly in-
dependent prognostic predictors of MAEs in PD patients (Table 2). We
also found thatmale gender, diabetesmellitus, increased pulse pressure,
and GLS ≥−15% were signiﬁcantly independent MACCE predictors in
PD patients (Table 2).jor adverse cardiovascular cerebral events (MACCEs).
MACCEs
iable Univariable Multivariable
CI) p HR (95% CI) p HR (95% CI) p
7–1.04) 0.80 1.02 (0.99–1.05) 0.18 0.99 (0.96–1.03) 0.71
5–5.31) 0.04 3.18 (1.38–7.33) 0.007 2.55 (1.09–5.98) 0.03
1–7.46) 0.03 6.38 (2.37–17.2) b0.001 2.44 (0.88–6.82) 0.09
– 5.92 (2.01–17.4) 0.001 – –
3–5.13) 0.02 3.75 (1.72–8.15) 0.001 2.30 (1.03–5.14) 0.04
8–5.56) 0.02 4.03 (1.83–8.90) 0.001 2.84 (1.27–6.35) 0.01
– 1.82 (0.83–4.01) 0.14 – –
– 0.60 (0.20–1.85) 0.38 – –
9–1.01) 0.64 1.01 (1.01–1.02) 0.002 1.00 (0.98–1.01) 0.55
6–4.78) 0.03 5.23 (2.33–11.7) b0.001 3.15 (1.38–7.18) 0.006
ular peak systolic longitudinal strain; LVMi, left ventricular mass index; RRF, residual renal
Fig. 1.Receiver operating characteristic (ROC) curves and corresponding area under the curve (AUC) ofmajor adverse events (MAEs) for left ventricular (LV) echocardiographic parameters:
LV end-diastolic volume index (LVEDVi), LV ejection fraction (LVEF), early to late diastolic trans-mitral velocity ratio (E/A), early trans-mitral velocity to tissue Dopplermitral annular early
diastolic velocity ratio (E/e′), LV systolic myocardial velocity (s′), and global LV peak systolic longitudinal strain (GLS). Only GLS had AUC value more than 0.7.
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we performed a bootstrap investigation with 3000 samples using the
same 7 variables. The bootstrap validation showed that the signiﬁcant
variables of MAEs were those selected in the original analysis with con-
ﬁdence intervals slightly larger than those from the original model;Fig. 2. Receiver operating characteristic (ROC) curves and corresponding area under the curve
echocardiographic parameters: LV end-diastolic volume index (LVEDVi), LV ejection fraction (
tissue Doppler mitral annular early diastolic velocity ratio (E/e′), LV systolic myocardial velocit
than 0.7.nevertheless, the signiﬁcance of male gender for MACCEs was border-
line (95% conﬁdence interval [CI]: 0.99 to 5.58, p= 0.052).
PD patients with GLS ≥ −15% had a worse prognosis, including
higher numbers of cardiac hospitalization episodes, scheduled revascu-
larization, MACCEs, and MAEs (Table 3). Moreover, Kaplan–Meier(AUC) of major adverse cardiovascular cerebral events (MACCEs) for left ventricular (LV)
LVEF), early to late diastolic trans-mitral velocity ratio (E/A), early trans-mitral velocity to
y (s′), and global LV peak systolic longitudinal strain (GLS). Only GLS had AUC value more
Table 3
Prognosis of peritoneal dialysis patients.
Reduced GLS
group
(GLS ≥ −15%,
n = 31)
Preserved GLS
group
(GLS b −15%,
n = 75)
p
Primary outcome
MAEs, n (%) 17 (55%) 12 (16%) b0.001
Secondary outcomes
All-cause mortality, n (%) 5 (16%) 4 (5%) 0.12
Cardiovascular death, n (%) 2 (6%) 0 0.08
Revascularization, n (%) 5 (16%) 2 (3%) 0.02
Admission due to heart
failure, n (%)
7 (23%) 0 (0%) b0.001
Admission due to cardiovascular
events, n (%)
12 (39%) 2 (3%) b0.001
Admission due to stroke, n (%) 3 (10%) 1 (1%) 0.07
New onset PAD with/without
PTA, n (%)
3 (10%) 5 (7%) 0.69
MACCEs, n (%) 17 (%) 9 (12%) b0.001
Abbreviations: GLS, global left ventricular peak systolic longitudinal strain;MACCEs,major
adverse cardiovascular cerebral events (including cardiovascular death, revascularization,
and admission due to cardiovascular events, [i.e. heart failure, angina, arrhythmia, and
fatal/non-fatal myocardial infarction], stroke); MAEs, major adverse events (including
MACCEs and all-cause mortality); PAD, peripheral artery occlusive disease; PTA, percuta-
neous transluminal angioplasty.
6 Y.-W. Liu et al. / IJC Heart & Vasculature 5 (2014) 1–8survival curves demonstrated signiﬁcant differences with respect to
MAEs,MACCEs, and cardiovascular events (Fig. 3). GLS added incremen-
tal prognostic information for MAEs and MACCEs based on a compari-
son of the overall log likelihood χ2 of the predictive power (Fig. 4).
3.3. Inter- and intra-rater variability
The intra- and inter-observer correlation coefﬁcients of the average
measures for GLSwere 0.98 (95% CI: 0.95 to 0.99) and 0.97 (95% CI: 0.94
to 0.99), respectively. A Bland–Altman analysis revealed no systemic
bias of GLS between intra- and inter-rater agreements. The mean
intra- and inter-rater differences [mean ± standard deviation (95%
limits of agreement)] for GLS were−0.02 ± 0.61 (−1.24 to 1.21) and
−0.26 ± 0.72 (−1.71 to 1.19), respectively.
4. Discussion
This is the ﬁrst study to demonstrate that GLS is a prognostic predic-
tor of MAEs and MACCEs in stable PD patients; furthermore, GLS adds
incremental prognostic information for clinically stable ESRD patients
receiving maintenance PD. In this prospective study of 106 clinicallyFig. 3. Kaplan–Meier estimates of (a) major adverse events, (b) major adverse cardiovascular ce
value for left ventricular global peak systolic longitudinal strain (GLS).stable PD patients, we identiﬁed powerful prognostic predictors of
MAEs and MACCEs, including a history of HF or diabetes, male gender,
an increased pulse pressure (≥60mmHg), and GLS≥−15%. It is note-
worthy that GLS provided addictive prognostic information to a model
based on the predictors of male gender, history of HF and diabetes,
and increased pulse pressure. Based on these data, we have validated
the clinical application of GLS for risk assessment in clinically stable
chronic PD patients.
Despite signiﬁcant improvement in dialysis modalities and medical
care, the high mortality and morbidity of ESRD patients remain impor-
tant and unresolved issues. Therefore, early identiﬁcation of high-risk pa-
tients may enable physicians to optimize therapeutic interventions and
improve the prognosis of dialysis patients. Several studies have focused
on this issue and discovered multiple prognostic predictors, including a
history of HF [30], increased pulse pressure [24], increased LVMi [31],
and serum biomarkers, such as hemoglobin [2], albumin [2], cardiac tro-
ponin T (cTnT) [31,32], and N-terminal pro-brain natriuretic peptide
(NT-pro-BNP) [33]. Moreover, increased NT-pro-BNP or cTnT levels
may suggest pathological cardiac structures and/or cardiac dysfunction
[31,34]. Although cardiac function in ESRD patients has been extensively
studied by measuring LVEF, LVMi, LAVi, and E/A, these conventional
echocardiographic parameters only provide a semi-quantitative evalua-
tion and cannot detect subclinical cardiac dysfunction [9]. Furthermore,
LV hypertrophy and reduced LVEF are recognized as prognostic predic-
tors in dialysis patients; however, most dialysis patients have LV hyper-
trophy and preserved LVEF (EF ≥ 50%), which may limit the clinical
application of LV hypertrophy and LVEF as prognostic factors [1,7,9]. As
a result, the detection of subtle LV systolic dysfunction is important to ac-
curately assess cardiac function in dialysis patients.
GLS has been shown to be amore accurate, reliable, and sensitive pa-
rameter for the assessment of LV systolic function in both HF patients
with preserved LVEF and chronic hemodialysis patients [11,12,14].
Importantly, our recent work also demonstrated the prognostic power
of GLS in clinically stable hemodialysis patients with preserved LVEF
[17]. Abnormal GLS (GLS≥−15%)may be the precursor of overt uremic
cardiomyopathy in dialysis patients. Although the mechanisms of ab-
normal GLS in ESRD patients are not fully elucidated, abnormal GLS rep-
resents subtle LV systolic dysfunction that has been shown to be
signiﬁcantly associated with poor prognosis in many studies [17,18,
35–37]. Furthermore, GLS ≥−15% may also be associated with micro-
vascular ischemia caused by the reduction in the density of myocardial
capillaries, myocardial ﬁbrosis, or dialysis-related myocardial stunning
[13,38–40]. The predictive value of GLS for long-term prognosis in clin-
ically stable ESRD patients undergoing chronic PD may be associated
with the myocardial abnormalities in ESRD patients that lead to a poor
prognosis.rebral events, and (c) cardiovascular events in peritoneal dialysis patients using the cutoff
Fig. 4. The incremental prognostic information of age, male gender, left ventricular mass index (LVMi), pulse pressure, underlying co-morbidities, and left ventricular global peak systolic
longitudinal strain (GLS) for (a) major adverse events and (b) major adverse cardiovascular cerebral events.
7Y.-W. Liu et al. / IJC Heart & Vasculature 5 (2014) 1–8This study has some limitations. First, although prevalent CAD was
not a prognostic predictor in our study population, we recognize that
the prognostic power of prevalent CADmay be underestimated because
of the relatively small number of included patients. Second, all the PD
patients were from a university hospital. We acknowledge that this
population may not represent the general PD patient population; thus,
our data should be cautiously applied to the overall PD population.
We did not measure NT-pro-BNP or cTnT levels in this study. Although
emerging evidence indicates the clinical relevance of NT-pro-BNP or
cTnT in PD patients, neither NT-pro-BNP nor cTnT can replace echocar-
diography in the evaluation of cardiac function and cardiovascular risk
proﬁle. More importantly, echocardiography can provide more infor-
mation than these serumbiomarkers. At last, because of the limited out-
come size and a signiﬁcant correlation between GLS and themajority of
conventional echocardiographicmeasurements, i.e. LVEDVi, LVMi, LVEF,
s′, and E/e′, we did not include these parameters inmulti-variate Cox re-
gression analysis. We recognized that there might be interactions that
cannot be assessed in the present study.5. Conclusions
Among clinically stable PD patients, male gender, a history of HF, in-
creased pulse pressure, and GLS ≥ −15% are predictive of MAEs and
MACCEs. The use of GLS added prognostic information to the clinical
predictors andmay allow for the early identiﬁcation of high-risk PD pa-
tients. These ﬁndings highlight the application of GLS in clinical practice.
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